Ticker HubNasdaq

CAPR

Capricor Therapeutics Inc

PHARMACEUTICAL PREPARATIONSLatest afterhours mover

Latest price

$6.92+4.37%

As of Oct 30, 2026, 8:00 PM EDT · Market data by Massive

Market cap

$385.5M

Volume

3.4M

Previous close

$6.63

Day range

$6.14 – $6.64

Listed

Jun 20, 2002

Coverage

0 articles

Price performance

Recent trading

5 trading days · 15-minute intervals · ET

Five-day open $5.94Latest interval $6.92

Newsroom

Latest CAPR coverage

No matching articles yet.

Recent catalyst headlines

CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears

Oct 21, 2026

CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision

Oct 7, 2026

Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears

Oct 7, 2026

Company overview

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 231
Headquarters: SAN DIEGO, CA
CIK: 0001133869

Company website View advanced chart

SEC filings

No filing records are attached to this profile yet.

Browse EDGAR

Profile at a glance

Jun 20, 2002

Listed

231

Employees

Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.